Merck & Co., Inc. (MRK) Stock Analysis
Merck & Co., Inc. (MRK) Stock Analysis
Analysis from 10-Q filed 2025-11-05. Data as of Q4 2025.
Overall Grade: F (Concerning)
Merck & Co., Inc. faces challenges in financial performance that warrant careful analysis.
| Metric | Value | Context |
|---|---|---|
| ROIC | 21.7% | Above industry average |
| FCF Margin | 19.0% | Strong cash generation |
| Debt/Equity | 0.9x | Moderate leverage |
Investment Thesis: Strong return on invested capital of 21.7% suggests durable competitive advantages and efficient capital allocation.
Explore Merck & Co., Inc.: Earnings History | Filing Intelligence | ROIC Analysis
Profitability: Merck & Co., Inc. earns 21.7% ROIC, Top 25% in Healthcare
Merck & Co., Inc.'s trailing-twelve-month ROIC of 21.7% ranks Top 25% in Healthcare companies (sector median: -3.9%), driven by NOPAT margin of 29.5% combined with asset turnover of 0.5x. Source: 10-Q filed 2025-11-05. Gross margin of 74.8% with operating margin at 34.0% reflects strong pricing power.
| Metric | MRK | Rating | Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 21.7% | Excellent | Above sector median of -3.9% |
| Return on Equity (ROE) | 36.8% | Excellent | Efficient use of shareholder equity |
| Gross Margin | 74.8% | Excellent | Strong pricing power |
| Operating Margin | 34.0% | Excellent | Efficient operations |
Cash Flow: Merck & Co., Inc. generates $12.4B FCF at 19.0% margin, positive NaN/8 quarters
Merck & Co., Inc. generated $12.4B in free cash flow (TTM), a 19.0% FCF margin, a margin that ranks Top 5% in Healthcare. FCF was positive in N/A of the last 8 quarters. Source: 10-Q filed 2025-11-05.
| Metric | MRK | Rating | Context |
|---|---|---|---|
| Free Cash Flow Margin | 19.0% | Good | Excellent cash conversion |
| Free Cash Flow (TTM) | $12.4B | Good | Positive cash generation |
| OCF/Net Income | 0.9x | Good | Potential accrual concerns |
| FCF Consistency (8Q) | N/A | Warning | Variable cash flow |
Balance Sheet: Merck & Co., Inc. at 0.9x leverage
Merck & Co., Inc.'s debt-to-equity ratio of 0.9x reflects elevated leverage. Total debt of $49.3B offset by $14.7B in cash. Source: 10-Q filed 2025-11-05.
| Metric | MRK | Rating | Context |
|---|---|---|---|
| Debt to Equity | 0.9x | Adequate | Moderate leverage |
| Net Cash Position | $-34.6B | Warning | Net debt position |
Valuation: Merck & Co., Inc. trades at 14.4x earnings
Merck & Co., Inc. trades at a P/E of 14.4x. Free cash flow yield of 4.7% reflects market expectations for growth.
| Metric | MRK | Rating | Context |
|---|---|---|---|
| P/E Ratio | 14.4x | Adequate | Reasonable valuation |
| EV/Sales | 4.5x | Good | Growth premium priced in |
| FCF Yield | 4.7% | Good | Lower cash yield |
| Dividend Yield | 3.1% | Adequate | Meaningful income |
Capital Allocation: Merck & Co., Inc. returns 5.0% shareholder yield
Merck & Co., Inc.'s total shareholder yield is 5.0% (dividends 3.1% + buybacks 1.9%). Source: 10-Q filed 2025-11-05.
| Metric | MRK | Rating | Context |
|---|---|---|---|
| Total Shareholder Yield | 5.0% | Good | Dividend + buyback yield combined |
| Buyback Yield | 1.9% | Adequate | Minimal buyback activity |
| Total Capital Returned (TTM) | $13.3B | Good | Dividends + buybacks returned to shareholders |
Sector Rankings
| Metric | Value | Percentile | vs Median |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 21.7% | Top 25% | - |
| Free Cash Flow Margin | 19.0% | Top 5% | - |
| Gross Margin | 74.8% | Top 50% | 1.2x above |
| Operating Margin | 34.0% | Top 25% | 17.7x above |
| Return on Equity (ROE) | 36.8% | Top 25% | - |
| P/E Ratio | 14.4x | N/A | - |
Financial Scorecard
| Metric | MRK | Rating | Sector Context |
|---|---|---|---|
| Return on Invested Capital (ROIC) | 21.7% | Excellent | Top 25% of sector (median: -3.9%) |
| Free Cash Flow Margin | 19.0% | Good | Top 5% of sector (median: 0.0%) |
| Gross Margin | 74.8% | Excellent | Top 50% of sector (median: 64.0%) |
| Debt to Equity Ratio | 93.8% | Adequate | Elevated but manageable |
| P/E Ratio (Price-to-Earnings) | 14.4x | Adequate | Attractively valued |
| Free Cash Flow Yield | 4.7% | Adequate | Moderate yield |
Frequently Asked Questions
Q: What is Merck & Co., Inc.'s Return on Invested Capital (ROIC)?
Merck & Co., Inc. (MRK) has a trailing twelve-month Return on Invested Capital (ROIC) of 21.7%. This compares above the sector median of -3.9%. An ROIC above 20% indicates exceptional capital efficiency and strong competitive advantages.
Q: What is Merck & Co., Inc.'s Free Cash Flow Margin?
Merck & Co., Inc. (MRK) has a free cash flow margin of 19.0%, generating $12.4 billion in free cash flow over the trailing twelve months. A FCF margin between 10-20% represents healthy cash generation for most industries.
Q: Is Merck & Co., Inc. stock overvalued or undervalued?
Merck & Co., Inc. (MRK) trades at a P/E ratio of 14.4x, which is above the sector median of N/A. The EV/Sales multiple is 4.5x. Free cash flow yield is 4.7%, which is in line with market averages.
Q: Does Merck & Co., Inc. pay a dividend?
Merck & Co., Inc. (MRK) currently pays a dividend yield of 3.1%. Including share buybacks, the total shareholder yield is 5.0%. This yield is moderate, suggesting a balance between income and growth reinvestment.
Q: How much debt does Merck & Co., Inc. have?
Merck & Co., Inc. (MRK) has a debt-to-equity ratio of 0.9x with total debt of $49.3 billion. Net debt position is $34.6 billion.
Q: What is Merck & Co., Inc.'s revenue and earnings growth?
Merck & Co., Inc. (MRK) grew revenue by 1.3% year-over-year. Earnings per share increased by 8.3% compared to the prior year. Modest growth indicates a mature business with stable demand.
Q: Is Merck & Co., Inc. buying back stock?
Merck & Co., Inc. (MRK) repurchased $5.1 billion of stock over the trailing twelve months. This represents a buyback yield of 1.9%.
Q: How does Merck & Co., Inc. compare to competitors in Healthcare?
Compared to other companies in Healthcare, Merck & Co., Inc. (MRK) shows: ROIC of 21.7% is above the sector median of -3.9% (Top 19%). FCF margin of 19.0% exceeds the sector median of 0.0% (Top 0% of sector). Gross margin at 74.8% is 10.8 percentage points higher than sector peers. These rankings are based on MetricDuck's analysis of all Healthcare companies with available SEC filings.
Q: What warning signs should I watch for with Merck & Co., Inc.?
Investors in Merck & Co., Inc. (MRK) should monitor these potential warning signs: 1) ROIC has been declining, potentially signaling deteriorating competitive position. Regular monitoring of SEC filings and quarterly trends is recommended.
Data Source: Data sourced from 10-Q filed 2025-11-05. TTM metrics as of Q4 2025.
Methodology: Financial metrics calculated from SEC 10-K and 10-Q filings using standardized formulas. Sector comparisons use peer group based on SIC code.
Scope: This analysis covers SEC filing fundamentals — profitability, cash flow, balance sheet, and valuation metrics. For analyst estimates and price targets, consult sell-side research.
This analysis is for informational purposes only and does not constitute investment advice.